You can buy or sell RIGL and other stocks, options, ETFs, and crypto commission-free!
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. Read More The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
South San Francisco, California
52 Week High
52 Week Low
Seeking AlphaMay 16
Rigel begins patient enrollment in late-stage AHIA study
Rigel Pharmaceuticals (NASDAQ:RIGL) has enrolled first patient in a Phase 3 trial of fostamatinib disodium hexahydrate in warm antibody autoimmune hemolytic anemia (AIHA). The trial protocol calls for ~80 patients in a 24-week study with topline results projected for early 2021. The primary endpoint will be a durable hemoglobin response by week 24, defined as Hgb > 10 g/dL and > 2 g/dL greater than baseline. Currently, fostamatinib is commercially available in U.S. under the brand name TAVALISSE. Rigel ...
Seeking AlphaMay 10
Rigel Reports An Earnings Beat, But The Market Shrugs It Off
Despite the positive updates, the share price remains in the lower $2.00 range. However, the charts show a systematic chart movement that is leading to a potential breakout. TAVALISSE appears to be gaining traction in the ITP market as physicians begin to move it up into earlier lines of therapy and above the competition. Rigel recently reported their Q1 earnings with a beat on EPS and revenue. Despite the good news, the market was unconcerned as the overall market is focused on trade talks. Rigel Pharma...
Expected Aug 7, After Hours